The company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback